Compugen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Compugen (CGEN).

Price Target Range — 6 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$5Upside to Avg. PT+118.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$4
May 21, 2026	Leerink Partners	—	PT Cut	Outperform	$13→$5
Apr 7, 2026	Lake Street	Chad Messer	Initiate	Buy	$6
Jan 7, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Initiate	Buy	$4
May 21, 2024	Truist Securities	Asthika Goonewardene	PT Cut	Buy	$5→$4
Mar 8, 2024	Truist Securities	Asthika Goonewardene	PT Raise	Buy	$4→$5
Dec 19, 2023	Stifel	Stephen Willey	PT Raise	Buy	$3→$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5

Leerink Partners maintains Compugen (NASDAQ:CGEN) with a Outperform and lowers the price target from $13 to $5.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6

Lake Street analyst Chad Messer initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating and announces Price Target of $6.

Benzinga Newsdesk

This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4

HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating and announces Price Target of $4.

Benzinga Newsdesk

Alterity Up on Interim Data From Advance MSA Study

Shares of Alterity Therapeutics (NASDAQ: ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy, a rare neurodegenerative disease.

Zacks

Compugen Ltd

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Compugen Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target

PRO
Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5

PRO
Lake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6

This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

PRO
HC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4

Alterity Up on Interim Data From Advance MSA Study

People Also Watch

People Also Watch

Compugen Ltd

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Compugen Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target

PROLeerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5

PROLake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6

This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

PROHC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4

Alterity Up on Interim Data From Advance MSA Study

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target

PRO
Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5

PRO
Lake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4